Whereas up to 2.2 million individuals in the United States are chronically infected with hepatitis B, and up to two-thirds of individuals with chronic hepatitis B are unaware of their infection status; Whereas hepatitis B is a viral infection of the liver transmitted via infected blood and other body fluids, including mother-to-child transmission and transmission through injection drug use; Whereas individuals with chronic diseases such as diabetes, HIV, hepatitis C, and chronic liver disease, and individuals on hemodialysis are at an increased risk for hepatitis B co-infection; Whereas there is no cure for hepatitis B and individuals with chronic hepatitis B require lifelong medical care; Whereas chronic hepatitis B represents one of the most common causes of liver cancer; Whereas 1 in every 4 individuals with unmanaged chronic hepatitis B will develop liver cancer, cirrhosis, or liver failure, with liver cancer only having an 18 percent 5-year survival rate in the United States; Whereas safe and highly effective vaccines to protect against hepatitis B are currently available and infants and children have been routinely vaccinated against hepatitis B since the 1990s in accordance with universal childhood hepatitis B vaccination recommendations in the United States; Whereas the hepatitis B vaccine, which is 95 percent effective and was the first anticancer vaccine to be developed, is projected to prevent 310 million cases of hepatitis B worldwide from 1990 to 2020; Whereas only 25 percent of adults are vaccinated against hepatitis B in the United States